How Often Do Pharmacies Make Mistakes When Dispensing Semaglutide Through Weight-Loss Apps?
Only 0.35% of semaglutide orders through Australia's largest app-based weight loss service contained dispensing errors, though incorrect dosing was the most common mistake.
Quick Facts
What This Study Found
Semaglutide dispensing errors occurred in only 0.35% of 28,165 orders, with incorrect dose being the most common error type at 58.6% of all errors.
Key Numbers
Australia's largest app-based semaglutide weight loss service. Dispensing error rates analyzed from pharmacy partners.
How They Did This
Retrospective cohort study analyzing dispensing error reports from patient-selected and partner pharmacies of Australia's largest digital weight loss service over six months.
Why This Research Matters
As GLP-1 medications become increasingly prescribed through digital health platforms, this study provides the first evidence that app-based dispensing error rates are relatively low, though dose errors remain a concern requiring vigilance.
The Bigger Picture
Digital weight loss services are rapidly expanding access to GLP-1 medications globally. Understanding their safety profile is critical as these platforms become a primary pathway for obesity treatment, and this data suggests they can operate with acceptably low error rates.
What This Study Doesn't Tell Us
Single provider in one country; relied on patient-reported errors which may undercount actual mistakes; six-month window may not capture seasonal patterns; no comparison to traditional pharmacy dispensing error rates.
Questions This Raises
- ?Why do women report dispensing errors at three times the rate of men — is this a reporting bias or a real difference?
- ?How do digital weight loss service error rates compare to traditional brick-and-mortar pharmacy rates?
- ?What system-level interventions could further reduce the most common error type of incorrect dosing?
Trust & Context
- Key Stat:
- 0.35% dispensing error rate across 28,165 semaglutide orders
- Evidence Grade:
- Preliminary evidence from a single digital health provider in Australia. While the sample size is large, it represents one service over six months with patient-reported outcomes only.
- Study Age:
- Published in 2024, reflecting current digital health practices in the GLP-1 prescribing landscape.
- Original Title:
- The Dispensing Error Rate in an App-Based, Semaglutide-Supported Weight-Loss Service: A Retrospective Cohort Study.
- Published In:
- Pharmacy (Basel, Switzerland), 12(5) (2024)
- Authors:
- Talay, Louis(3), Vickers, Matt(2)
- Database ID:
- RPEP-09362
Evidence Hierarchy
Frequently Asked Questions
How common are errors when getting semaglutide through an app-based weight loss service?
Very uncommon — only about 1 in 285 orders (0.35%) had an error. The most common mistake was receiving the wrong dose, which accounted for nearly 60% of all errors.
Are app-based weight loss services safe for getting semaglutide prescriptions?
This study suggests they are relatively safe, with low error rates comparable to or below traditional pharmacy benchmarks. However, patients should always verify their dose before injecting.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09362APA
Talay, Louis; Vickers, Matt. (2024). The Dispensing Error Rate in an App-Based, Semaglutide-Supported Weight-Loss Service: A Retrospective Cohort Study.. Pharmacy (Basel, Switzerland), 12(5). https://doi.org/10.3390/pharmacy12050135
MLA
Talay, Louis, et al. "The Dispensing Error Rate in an App-Based, Semaglutide-Supported Weight-Loss Service: A Retrospective Cohort Study.." Pharmacy (Basel, 2024. https://doi.org/10.3390/pharmacy12050135
RethinkPeptides
RethinkPeptides Research Database. "The Dispensing Error Rate in an App-Based, Semaglutide-Suppo..." RPEP-09362. Retrieved from https://rethinkpeptides.com/research/talay-2024-the-dispensing-error-rate
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.